Walvaxysb88会员登录网址易胜博最新地址

  • Our Company
  • Our Journey
  • Contact Us
  • Value of Vaccines
  • Products List
  • Production
  • Distribution
  • R&D Platform
  • Pipeline
  • Investors
  • Media
  • Collaborations
  • Career
  • Responsibility
  • Our Company
  • Our Journey
  • Contact Us
  • Value of Vaccines
  • Products List
  • Production
  • Distribution
  • R&D Platform
  • Pipeline
  • Investors
  • Media
  • Collaborations
  • Career
  • Responsibility
  • CN
    EN

    Products List

    Walvax has successfully developed 7 licensed vaccines, including recently approved 13-valent Pneumococcal Conjugate Vaccine (PCV13-TT), one of the most difficult vaccines to develop in the world.

     

    Walvax proactively promotes PQ application of its products, and is proceeding with PQ application of 5 products. In 3 to 5 years, Walvax's WHO-PQ will yield fruitful results, which brings its internationalization to a higher level.

    Quick Links

    Pipeline
    13-valent Pneumococcal Polysaccharide Conjugate Vaccine

    Prevention of invasive diseases caused by 13 serotypes of Streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age (below 6 years).

    23-valent Pneumococcal Polysaccharide Vaccine

    Prevention of invasive diseases caused by 23 serotypes of Streptococcus pneumoniae for use in individuals aged ≥ 2 years who are at increased risk of pneumococcal diseases.

    Group ACYW135 Meningococcal Polysaccharide Vaccine

    Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, Y and W135 for use in individuals aged ≥ 2 years.

    Group A and C Meningococcal Polysaccharide Vaccine

    Prevention of epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A and C for use in individuals aged ≥ 2 years.

    Group A and Group C Meningococcal Conjugate Vaccine

    Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for use in infants and children 3 months through 5 years of age.

    Haemophilus Influenzae Type b Conjugate Vaccine

    Prevention of invasive infections caused by Haemophilus Influenzae type b for infants and children 2 months through 5 years of age.

    Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed

    Prevention of pertussis, diphtheria and tetanus for infants and children 3 months through 6 years of age.